Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) provided updates on its lead product candidate, DURAVYU™, and key milestones for 2025. The company reported strong enrollment in its Phase 3 wet AMD clinical trials, with LUGANO being one-third enrolled and LUCIA ahead of schedule. Both trials are expected to complete enrollment in H2 2025, with topline data in 2026.
The company highlighted positive interim results from the Phase 2 VERONA trial in DME, with full data expected in Q1 2025. DURAVYU demonstrated meaningful improvements in patients with active DME, showing CST improvement of 68.1 microns and BCVA gain of +8.9 letters vs. baseline.
Notable corporate updates include the appointment of Dr. Reginald J. Sanders to the Board and the opening of a new 40,000+ square-foot manufacturing facility in Northbridge, MA. The company reported approximately $370 million in cash and investments as of December 31, 2024, with runway extending into 2027.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Dr. Reginald J. Sanders, a prominent retina specialist, to its Board of Directors. Dr. Sanders, the most recent President of the American Society of Retina Specialists, brings extensive clinical and business development experience in retinal diseases.
The appointment comes at a important time as EyePoint advances its global phase 3 pivotal trials for wet AMD and following positive interim data from its Phase 2 trial in diabetic macular edema. Dr. Sanders has significant experience as a principal investigator, including work on Lucentis® for wet AMD treatment, and has published over 50 papers. He currently serves as a board member of Prism Vision Group and is affiliated with the Retina Group of Washington, which he helped build into the largest retinal specialist practice in the United States.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jay S. Duker, M.D., the company's President and CEO, will deliver a presentation on January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET in San Francisco. Investors and interested parties can access the presentation webcast and replay through the Investors section of EyePoint's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to six new employees as inducement awards. The grants, approved by the Compensation Committee on December 13, 2024, include options to purchase up to 54,600 shares of common stock at an exercise price of $7.46 per share. These options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years. The awards were made outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated dosing in LUCIA, its second global Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD) treatment. DURAVYU delivers vorolanib through the proprietary Durasert E™ platform for sustained intraocular delivery.
The LUCIA and LUGANO Phase 3 trials will each enroll approximately 400 patients globally, comparing a 2.7mg DURAVYU dose to aflibercept. DURAVYU will be administered every six months, starting at month two. The primary endpoint is the average change in best corrected visual acuity at weeks 52 and 56 versus baseline.
With over 240 global sites committed and strong patient interest, EyePoint expects topline data in 2026. These trials are notable as the first and only sustained release wet AMD pivotal program evaluating re-dosing in both studies.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards. The grants, approved by the Compensation Committee, include options to purchase up to 23,600 shares at an exercise price of $9.17 per share, based on the closing price on November 15, 2024. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals reported Q3 2024 financial results and corporate updates. Key highlights include positive interim data for DURAVYU 2.7mg in DME showing +8.9 letters BCVA improvement and -68 microns CST reduction at 16 weeks. The company initiated Phase 3 LUGANO trial for wet AMD and completed a $161M equity financing. Q3 revenue was $10.5M, down from $15.2M in Q3 2023. Net loss increased to $29.4M ($0.54 per share) from $12.6M ($0.33 per share) year-over-year. Cash position stands at $253.8M, with runway extended into 2027 following the recent financing.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in four upcoming investor conferences in November and December 2024. The company will participate in Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11), UBS Global Healthcare Conference (Nov 13), Jefferies London Healthcare Conference (Nov 19), and BTIG 4th Annual Ophthalmology Day (Dec 2). Each event will feature either a fireside chat or corporate presentation format. Live webcasts and replays will be available through the Investors section of EyePoint's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has successfully closed its upsized public offering of 14,636,363 shares of common stock at $11.00 per share, including the full exercise of underwriters' option for additional 1,909,090 shares. The offering generated gross proceeds of approximately $161.0 million. The company plans to use the proceeds to advance clinical development of DURAVYU™ for wet AMD and DME, support early-stage pipeline initiatives, and for general corporate purposes. J.P. Morgan, Citigroup, and Guggenheim Securities served as joint book running managers.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the pricing of an upsized public offering of 12,727,273 shares of common stock at $11.00 per share, expecting to raise approximately $140.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to an additional 1,909,090 shares. The offering is expected to close around October 31, 2024. The proceeds will be used to advance clinical development of DURAVYU™ for wet AMD and DME, support pipeline development initiatives, and general corporate purposes.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
